nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP2C9—Capecitabine—colon cancer	0.0748	0.265	CbGbCtD
Irbesartan—CYP2C8—Fluorouracil—colon cancer	0.0636	0.225	CbGbCtD
Irbesartan—CYP1A2—Fluorouracil—colon cancer	0.0493	0.174	CbGbCtD
Irbesartan—CYP2C9—Fluorouracil—colon cancer	0.0444	0.157	CbGbCtD
Irbesartan—CYP3A4—Irinotecan—colon cancer	0.0269	0.0952	CbGbCtD
Irbesartan—CYP3A4—Vincristine—colon cancer	0.0235	0.0832	CbGbCtD
Irbesartan—JUN—endothelium—colon cancer	0.0104	0.0754	CbGeAlD
Irbesartan—JUN—blood vessel—colon cancer	0.00955	0.0695	CbGeAlD
Irbesartan—AGTR1—endothelium—colon cancer	0.00779	0.0567	CbGeAlD
Irbesartan—AGTR1—blood vessel—colon cancer	0.00719	0.0523	CbGeAlD
Irbesartan—UGT1A3—digestive system—colon cancer	0.00625	0.0455	CbGeAlD
Irbesartan—JUN—embryo—colon cancer	0.00569	0.0415	CbGeAlD
Irbesartan—UGT1A3—liver—colon cancer	0.00465	0.0339	CbGeAlD
Irbesartan—JUN—epithelium—colon cancer	0.00465	0.0338	CbGeAlD
Irbesartan—JUN—smooth muscle tissue—colon cancer	0.00448	0.0326	CbGeAlD
Irbesartan—JUN—renal system—colon cancer	0.00431	0.0314	CbGeAlD
Irbesartan—JUN—lymphoid tissue—colon cancer	0.00358	0.0261	CbGeAlD
Irbesartan—JUN—digestive system—colon cancer	0.00353	0.0257	CbGeAlD
Irbesartan—AGTR1—epithelium—colon cancer	0.0035	0.0255	CbGeAlD
Irbesartan—PTGS1—endothelium—colon cancer	0.00343	0.0249	CbGeAlD
Irbesartan—EDNRA—vagina—colon cancer	0.00342	0.0249	CbGeAlD
Irbesartan—AGTR1—smooth muscle tissue—colon cancer	0.00337	0.0245	CbGeAlD
Irbesartan—JUN—bone marrow—colon cancer	0.00326	0.0237	CbGeAlD
Irbesartan—AGTR1—renal system—colon cancer	0.00325	0.0236	CbGeAlD
Irbesartan—PTGS1—blood vessel—colon cancer	0.00316	0.023	CbGeAlD
Irbesartan—JUN—vagina—colon cancer	0.00312	0.0227	CbGeAlD
Irbesartan—AGTR1—lymphoid tissue—colon cancer	0.00269	0.0196	CbGeAlD
Irbesartan—JUN—liver—colon cancer	0.00263	0.0192	CbGeAlD
Irbesartan—AGTR1—vagina—colon cancer	0.00235	0.0171	CbGeAlD
Irbesartan—EDNRA—lymph node—colon cancer	0.00221	0.0161	CbGeAlD
Irbesartan—JUN—lymph node—colon cancer	0.00202	0.0147	CbGeAlD
Irbesartan—AGTR1—liver—colon cancer	0.00198	0.0144	CbGeAlD
Irbesartan—CYP2C8—renal system—colon cancer	0.00176	0.0128	CbGeAlD
Irbesartan—CYP1A2—renal system—colon cancer	0.00165	0.012	CbGeAlD
Irbesartan—PTGS1—epithelium—colon cancer	0.00154	0.0112	CbGeAlD
Irbesartan—AGTR1—lymph node—colon cancer	0.00152	0.0111	CbGeAlD
Irbesartan—PTGS1—smooth muscle tissue—colon cancer	0.00148	0.0108	CbGeAlD
Irbesartan—PTGS1—renal system—colon cancer	0.00143	0.0104	CbGeAlD
Irbesartan—CYP1A2—digestive system—colon cancer	0.00135	0.00983	CbGeAlD
Irbesartan—CYP2C9—digestive system—colon cancer	0.00128	0.00933	CbGeAlD
Irbesartan—CYP2C8—vagina—colon cancer	0.00127	0.00928	CbGeAlD
Irbesartan—CYP3A4—renal system—colon cancer	0.00119	0.00868	CbGeAlD
Irbesartan—CYP2D6—renal system—colon cancer	0.00117	0.00854	CbGeAlD
Irbesartan—PTGS1—digestive system—colon cancer	0.00117	0.00852	CbGeAlD
Irbesartan—CYP2C8—liver—colon cancer	0.00108	0.00783	CbGeAlD
Irbesartan—PTGS1—vagina—colon cancer	0.00103	0.00752	CbGeAlD
Irbesartan—CYP1A2—liver—colon cancer	0.00101	0.00732	CbGeAlD
Irbesartan—CYP3A4—digestive system—colon cancer	0.000977	0.00712	CbGeAlD
Irbesartan—CYP2D6—digestive system—colon cancer	0.000962	0.007	CbGeAlD
Irbesartan—CYP2C9—liver—colon cancer	0.000955	0.00695	CbGeAlD
Irbesartan—CYP3A4—liver—colon cancer	0.000728	0.0053	CbGeAlD
Irbesartan—CYP2D6—liver—colon cancer	0.000717	0.00522	CbGeAlD
Irbesartan—PTGS1—lymph node—colon cancer	0.000668	0.00487	CbGeAlD
Irbesartan—Candesartan—ABCB1—colon cancer	0.000665	0.608	CrCbGaD
Irbesartan—Pneumonia—Capecitabine—colon cancer	0.000603	0.00187	CcSEcCtD
Irbesartan—Leukopenia—Fluorouracil—colon cancer	0.0006	0.00186	CcSEcCtD
Irbesartan—Acute coronary syndrome—Capecitabine—colon cancer	0.000591	0.00183	CcSEcCtD
Irbesartan—Cerebrovascular accident—Methotrexate—colon cancer	0.000591	0.00183	CcSEcCtD
Irbesartan—Renal failure—Capecitabine—colon cancer	0.000589	0.00183	CcSEcCtD
Irbesartan—Discomfort—Irinotecan—colon cancer	0.000589	0.00182	CcSEcCtD
Irbesartan—Myocardial infarction—Capecitabine—colon cancer	0.000588	0.00182	CcSEcCtD
Irbesartan—Anaphylactic shock—Vincristine—colon cancer	0.000587	0.00182	CcSEcCtD
Irbesartan—Oedema—Vincristine—colon cancer	0.000587	0.00182	CcSEcCtD
Irbesartan—Jaundice—Capecitabine—colon cancer	0.000584	0.00181	CcSEcCtD
Irbesartan—Infection—Vincristine—colon cancer	0.000583	0.00181	CcSEcCtD
Irbesartan—Urinary tract infection—Capecitabine—colon cancer	0.000583	0.00181	CcSEcCtD
Irbesartan—Conjunctivitis—Capecitabine—colon cancer	0.000583	0.00181	CcSEcCtD
Irbesartan—Nervous system disorder—Vincristine—colon cancer	0.000575	0.00178	CcSEcCtD
Irbesartan—Thrombocytopenia—Vincristine—colon cancer	0.000574	0.00178	CcSEcCtD
Irbesartan—Oedema—Irinotecan—colon cancer	0.000571	0.00177	CcSEcCtD
Irbesartan—Anaphylactic shock—Irinotecan—colon cancer	0.000571	0.00177	CcSEcCtD
Irbesartan—Chest pain—Fluorouracil—colon cancer	0.000571	0.00177	CcSEcCtD
Irbesartan—Myalgia—Fluorouracil—colon cancer	0.000571	0.00177	CcSEcCtD
Irbesartan—Infection—Irinotecan—colon cancer	0.000567	0.00176	CcSEcCtD
Irbesartan—Hyperhidrosis—Vincristine—colon cancer	0.000567	0.00176	CcSEcCtD
Irbesartan—Hepatobiliary disease—Capecitabine—colon cancer	0.000567	0.00176	CcSEcCtD
Irbesartan—Epistaxis—Capecitabine—colon cancer	0.000565	0.00175	CcSEcCtD
Irbesartan—Discomfort—Fluorouracil—colon cancer	0.000564	0.00175	CcSEcCtD
Irbesartan—Shock—Irinotecan—colon cancer	0.000562	0.00174	CcSEcCtD
Irbesartan—Nervous system disorder—Irinotecan—colon cancer	0.00056	0.00174	CcSEcCtD
Irbesartan—Agranulocytosis—Capecitabine—colon cancer	0.000559	0.00173	CcSEcCtD
Irbesartan—Thrombocytopenia—Irinotecan—colon cancer	0.000559	0.00173	CcSEcCtD
Irbesartan—Anorexia—Vincristine—colon cancer	0.000559	0.00173	CcSEcCtD
Irbesartan—Hyperhidrosis—Irinotecan—colon cancer	0.000552	0.00171	CcSEcCtD
Irbesartan—Mood swings—Methotrexate—colon cancer	0.000549	0.0017	CcSEcCtD
Irbesartan—Hypotension—Vincristine—colon cancer	0.000548	0.0017	CcSEcCtD
Irbesartan—Bradycardia—Capecitabine—colon cancer	0.000548	0.0017	CcSEcCtD
Irbesartan—Anaphylactic shock—Fluorouracil—colon cancer	0.000547	0.0017	CcSEcCtD
Irbesartan—Oedema—Fluorouracil—colon cancer	0.000547	0.0017	CcSEcCtD
Irbesartan—Anorexia—Irinotecan—colon cancer	0.000544	0.00169	CcSEcCtD
Irbesartan—Infection—Fluorouracil—colon cancer	0.000544	0.00168	CcSEcCtD
Irbesartan—Rhinitis—Capecitabine—colon cancer	0.000539	0.00167	CcSEcCtD
Irbesartan—Hepatitis—Capecitabine—colon cancer	0.000538	0.00167	CcSEcCtD
Irbesartan—Nervous system disorder—Fluorouracil—colon cancer	0.000537	0.00166	CcSEcCtD
Irbesartan—Thrombocytopenia—Fluorouracil—colon cancer	0.000536	0.00166	CcSEcCtD
Irbesartan—Hypoaesthesia—Capecitabine—colon cancer	0.000535	0.00166	CcSEcCtD
Irbesartan—Liver function test abnormal—Methotrexate—colon cancer	0.000535	0.00166	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Vincristine—colon cancer	0.000534	0.00166	CcSEcCtD
Irbesartan—Pharyngitis—Capecitabine—colon cancer	0.000534	0.00165	CcSEcCtD
Irbesartan—Tachycardia—Fluorouracil—colon cancer	0.000534	0.00165	CcSEcCtD
Irbesartan—Hypotension—Irinotecan—colon cancer	0.000534	0.00165	CcSEcCtD
Irbesartan—Urinary tract disorder—Capecitabine—colon cancer	0.000531	0.00165	CcSEcCtD
Irbesartan—Oedema peripheral—Capecitabine—colon cancer	0.00053	0.00164	CcSEcCtD
Irbesartan—Connective tissue disorder—Capecitabine—colon cancer	0.000529	0.00164	CcSEcCtD
Irbesartan—Urethral disorder—Capecitabine—colon cancer	0.000527	0.00163	CcSEcCtD
Irbesartan—Paraesthesia—Vincristine—colon cancer	0.000527	0.00163	CcSEcCtD
Irbesartan—Breast disorder—Methotrexate—colon cancer	0.000523	0.00162	CcSEcCtD
Irbesartan—Anorexia—Fluorouracil—colon cancer	0.000521	0.00162	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000521	0.00162	CcSEcCtD
Irbesartan—Visual impairment—Capecitabine—colon cancer	0.000519	0.00161	CcSEcCtD
Irbesartan—Paraesthesia—Irinotecan—colon cancer	0.000513	0.00159	CcSEcCtD
Irbesartan—Hypotension—Fluorouracil—colon cancer	0.000511	0.00158	CcSEcCtD
Irbesartan—Decreased appetite—Vincristine—colon cancer	0.00051	0.00158	CcSEcCtD
Irbesartan—Dyspnoea—Irinotecan—colon cancer	0.000509	0.00158	CcSEcCtD
Irbesartan—Somnolence—Irinotecan—colon cancer	0.000508	0.00157	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Vincristine—colon cancer	0.000506	0.00157	CcSEcCtD
Irbesartan—Fatigue—Vincristine—colon cancer	0.000506	0.00157	CcSEcCtD
Irbesartan—Dyspepsia—Irinotecan—colon cancer	0.000503	0.00156	CcSEcCtD
Irbesartan—Tinnitus—Capecitabine—colon cancer	0.000502	0.00155	CcSEcCtD
Irbesartan—Constipation—Vincristine—colon cancer	0.000502	0.00155	CcSEcCtD
Irbesartan—Pain—Vincristine—colon cancer	0.000502	0.00155	CcSEcCtD
Irbesartan—Asthma—Methotrexate—colon cancer	0.0005	0.00155	CcSEcCtD
Irbesartan—Flushing—Capecitabine—colon cancer	0.000499	0.00155	CcSEcCtD
Irbesartan—Cardiac disorder—Capecitabine—colon cancer	0.000499	0.00155	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000498	0.00154	CcSEcCtD
Irbesartan—Decreased appetite—Irinotecan—colon cancer	0.000497	0.00154	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Irinotecan—colon cancer	0.000493	0.00153	CcSEcCtD
Irbesartan—Fatigue—Irinotecan—colon cancer	0.000492	0.00153	CcSEcCtD
Irbesartan—Paraesthesia—Fluorouracil—colon cancer	0.000491	0.00152	CcSEcCtD
Irbesartan—Pancreatitis—Methotrexate—colon cancer	0.000491	0.00152	CcSEcCtD
Irbesartan—Constipation—Irinotecan—colon cancer	0.000488	0.00151	CcSEcCtD
Irbesartan—Pain—Irinotecan—colon cancer	0.000488	0.00151	CcSEcCtD
Irbesartan—Angiopathy—Capecitabine—colon cancer	0.000488	0.00151	CcSEcCtD
Irbesartan—Dyspnoea—Fluorouracil—colon cancer	0.000488	0.00151	CcSEcCtD
Irbesartan—Somnolence—Fluorouracil—colon cancer	0.000486	0.00151	CcSEcCtD
Irbesartan—Immune system disorder—Capecitabine—colon cancer	0.000486	0.00151	CcSEcCtD
Irbesartan—Mediastinal disorder—Capecitabine—colon cancer	0.000485	0.0015	CcSEcCtD
Irbesartan—Chills—Capecitabine—colon cancer	0.000483	0.0015	CcSEcCtD
Irbesartan—Dyspepsia—Fluorouracil—colon cancer	0.000482	0.00149	CcSEcCtD
Irbesartan—Arrhythmia—Capecitabine—colon cancer	0.000481	0.00149	CcSEcCtD
Irbesartan—Gastrointestinal pain—Vincristine—colon cancer	0.00048	0.00149	CcSEcCtD
Irbesartan—Decreased appetite—Fluorouracil—colon cancer	0.000476	0.00147	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000472	0.00146	CcSEcCtD
Irbesartan—Feeling abnormal—Irinotecan—colon cancer	0.000471	0.00146	CcSEcCtD
Irbesartan—Erythema—Capecitabine—colon cancer	0.000468	0.00145	CcSEcCtD
Irbesartan—Malnutrition—Capecitabine—colon cancer	0.000468	0.00145	CcSEcCtD
Irbesartan—Neutropenia—Methotrexate—colon cancer	0.000468	0.00145	CcSEcCtD
Irbesartan—Pain—Fluorouracil—colon cancer	0.000468	0.00145	CcSEcCtD
Irbesartan—Gastrointestinal pain—Irinotecan—colon cancer	0.000467	0.00145	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Methotrexate—colon cancer	0.000465	0.00144	CcSEcCtD
Irbesartan—Abdominal pain—Vincristine—colon cancer	0.000464	0.00144	CcSEcCtD
Irbesartan—Body temperature increased—Vincristine—colon cancer	0.000464	0.00144	CcSEcCtD
Irbesartan—Flatulence—Capecitabine—colon cancer	0.000462	0.00143	CcSEcCtD
Irbesartan—Dysgeusia—Capecitabine—colon cancer	0.000459	0.00142	CcSEcCtD
Irbesartan—Photosensitivity reaction—Methotrexate—colon cancer	0.000457	0.00142	CcSEcCtD
Irbesartan—Abdominal pain—Irinotecan—colon cancer	0.000452	0.0014	CcSEcCtD
Irbesartan—Body temperature increased—Irinotecan—colon cancer	0.000452	0.0014	CcSEcCtD
Irbesartan—Feeling abnormal—Fluorouracil—colon cancer	0.000451	0.0014	CcSEcCtD
Irbesartan—Muscle spasms—Capecitabine—colon cancer	0.00045	0.0014	CcSEcCtD
Irbesartan—Pneumonia—Methotrexate—colon cancer	0.000449	0.00139	CcSEcCtD
Irbesartan—Vision blurred—Capecitabine—colon cancer	0.000441	0.00137	CcSEcCtD
Irbesartan—Tremor—Capecitabine—colon cancer	0.000439	0.00136	CcSEcCtD
Irbesartan—Renal failure—Methotrexate—colon cancer	0.000439	0.00136	CcSEcCtD
Irbesartan—Ill-defined disorder—Capecitabine—colon cancer	0.000435	0.00135	CcSEcCtD
Irbesartan—Urticaria—Fluorouracil—colon cancer	0.000435	0.00135	CcSEcCtD
Irbesartan—Conjunctivitis—Methotrexate—colon cancer	0.000434	0.00134	CcSEcCtD
Irbesartan—Anaemia—Capecitabine—colon cancer	0.000433	0.00134	CcSEcCtD
Irbesartan—Body temperature increased—Fluorouracil—colon cancer	0.000432	0.00134	CcSEcCtD
Irbesartan—Hypersensitivity—Vincristine—colon cancer	0.000432	0.00134	CcSEcCtD
Irbesartan—Losartan—ABCB1—colon cancer	0.000429	0.392	CrCbGaD
Irbesartan—Malaise—Capecitabine—colon cancer	0.000422	0.00131	CcSEcCtD
Irbesartan—Hepatobiliary disease—Methotrexate—colon cancer	0.000422	0.00131	CcSEcCtD
Irbesartan—Epistaxis—Methotrexate—colon cancer	0.000421	0.0013	CcSEcCtD
Irbesartan—Vertigo—Capecitabine—colon cancer	0.000421	0.0013	CcSEcCtD
Irbesartan—Hypersensitivity—Irinotecan—colon cancer	0.000421	0.0013	CcSEcCtD
Irbesartan—Asthenia—Vincristine—colon cancer	0.000421	0.0013	CcSEcCtD
Irbesartan—Syncope—Capecitabine—colon cancer	0.00042	0.0013	CcSEcCtD
Irbesartan—Leukopenia—Capecitabine—colon cancer	0.000419	0.0013	CcSEcCtD
Irbesartan—Agranulocytosis—Methotrexate—colon cancer	0.000416	0.00129	CcSEcCtD
Irbesartan—Loss of consciousness—Capecitabine—colon cancer	0.000412	0.00128	CcSEcCtD
Irbesartan—Asthenia—Irinotecan—colon cancer	0.00041	0.00127	CcSEcCtD
Irbesartan—Cough—Capecitabine—colon cancer	0.000409	0.00127	CcSEcCtD
Irbesartan—Hypertension—Capecitabine—colon cancer	0.000404	0.00125	CcSEcCtD
Irbesartan—Hypersensitivity—Fluorouracil—colon cancer	0.000403	0.00125	CcSEcCtD
Irbesartan—Diarrhoea—Vincristine—colon cancer	0.000401	0.00124	CcSEcCtD
Irbesartan—Hepatitis—Methotrexate—colon cancer	0.000401	0.00124	CcSEcCtD
Irbesartan—Chest pain—Capecitabine—colon cancer	0.000399	0.00124	CcSEcCtD
Irbesartan—Myalgia—Capecitabine—colon cancer	0.000399	0.00124	CcSEcCtD
Irbesartan—Arthralgia—Capecitabine—colon cancer	0.000399	0.00124	CcSEcCtD
Irbesartan—Pharyngitis—Methotrexate—colon cancer	0.000398	0.00123	CcSEcCtD
Irbesartan—Anxiety—Capecitabine—colon cancer	0.000397	0.00123	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000396	0.00123	CcSEcCtD
Irbesartan—Urinary tract disorder—Methotrexate—colon cancer	0.000396	0.00123	CcSEcCtD
Irbesartan—Discomfort—Capecitabine—colon cancer	0.000394	0.00122	CcSEcCtD
Irbesartan—Urethral disorder—Methotrexate—colon cancer	0.000393	0.00122	CcSEcCtD
Irbesartan—Diarrhoea—Irinotecan—colon cancer	0.000391	0.00121	CcSEcCtD
Irbesartan—Dry mouth—Capecitabine—colon cancer	0.00039	0.00121	CcSEcCtD
Irbesartan—Dizziness—Vincristine—colon cancer	0.000388	0.0012	CcSEcCtD
Irbesartan—Pruritus—Fluorouracil—colon cancer	0.000387	0.0012	CcSEcCtD
Irbesartan—Visual impairment—Methotrexate—colon cancer	0.000386	0.0012	CcSEcCtD
Irbesartan—Oedema—Capecitabine—colon cancer	0.000382	0.00118	CcSEcCtD
Irbesartan—Infection—Capecitabine—colon cancer	0.00038	0.00118	CcSEcCtD
Irbesartan—Dizziness—Irinotecan—colon cancer	0.000378	0.00117	CcSEcCtD
Irbesartan—Shock—Capecitabine—colon cancer	0.000376	0.00117	CcSEcCtD
Irbesartan—Nervous system disorder—Capecitabine—colon cancer	0.000375	0.00116	CcSEcCtD
Irbesartan—Diarrhoea—Fluorouracil—colon cancer	0.000374	0.00116	CcSEcCtD
Irbesartan—Thrombocytopenia—Capecitabine—colon cancer	0.000374	0.00116	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—colon cancer	0.000373	0.00116	CcSEcCtD
Irbesartan—Tachycardia—Capecitabine—colon cancer	0.000373	0.00116	CcSEcCtD
Irbesartan—Vomiting—Vincristine—colon cancer	0.000373	0.00116	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—colon cancer	0.000372	0.00115	CcSEcCtD
Irbesartan—Skin disorder—Capecitabine—colon cancer	0.000371	0.00115	CcSEcCtD
Irbesartan—Rash—Vincristine—colon cancer	0.00037	0.00115	CcSEcCtD
Irbesartan—Hyperhidrosis—Capecitabine—colon cancer	0.00037	0.00115	CcSEcCtD
Irbesartan—Dermatitis—Vincristine—colon cancer	0.000369	0.00114	CcSEcCtD
Irbesartan—Headache—Vincristine—colon cancer	0.000367	0.00114	CcSEcCtD
Irbesartan—Anorexia—Capecitabine—colon cancer	0.000364	0.00113	CcSEcCtD
Irbesartan—Angiopathy—Methotrexate—colon cancer	0.000363	0.00113	CcSEcCtD
Irbesartan—Vomiting—Irinotecan—colon cancer	0.000363	0.00113	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—colon cancer	0.000362	0.00112	CcSEcCtD
Irbesartan—Dizziness—Fluorouracil—colon cancer	0.000362	0.00112	CcSEcCtD
Irbesartan—Mediastinal disorder—Methotrexate—colon cancer	0.000361	0.00112	CcSEcCtD
Irbesartan—Rash—Irinotecan—colon cancer	0.00036	0.00112	CcSEcCtD
Irbesartan—Dermatitis—Irinotecan—colon cancer	0.00036	0.00111	CcSEcCtD
Irbesartan—Chills—Methotrexate—colon cancer	0.000359	0.00111	CcSEcCtD
Irbesartan—Headache—Irinotecan—colon cancer	0.000358	0.00111	CcSEcCtD
Irbesartan—Hypotension—Capecitabine—colon cancer	0.000357	0.00111	CcSEcCtD
Irbesartan—Malnutrition—Methotrexate—colon cancer	0.000349	0.00108	CcSEcCtD
Irbesartan—Erythema—Methotrexate—colon cancer	0.000349	0.00108	CcSEcCtD
Irbesartan—Nausea—Vincristine—colon cancer	0.000348	0.00108	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000348	0.00108	CcSEcCtD
Irbesartan—Vomiting—Fluorouracil—colon cancer	0.000348	0.00108	CcSEcCtD
Irbesartan—Rash—Fluorouracil—colon cancer	0.000345	0.00107	CcSEcCtD
Irbesartan—Dermatitis—Fluorouracil—colon cancer	0.000345	0.00107	CcSEcCtD
Irbesartan—Paraesthesia—Capecitabine—colon cancer	0.000343	0.00106	CcSEcCtD
Irbesartan—Headache—Fluorouracil—colon cancer	0.000343	0.00106	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—colon cancer	0.000341	0.00106	CcSEcCtD
Irbesartan—Dyspnoea—Capecitabine—colon cancer	0.000341	0.00106	CcSEcCtD
Irbesartan—Nausea—Irinotecan—colon cancer	0.000339	0.00105	CcSEcCtD
Irbesartan—Dyspepsia—Capecitabine—colon cancer	0.000337	0.00104	CcSEcCtD
Irbesartan—Decreased appetite—Capecitabine—colon cancer	0.000332	0.00103	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Capecitabine—colon cancer	0.00033	0.00102	CcSEcCtD
Irbesartan—Fatigue—Capecitabine—colon cancer	0.00033	0.00102	CcSEcCtD
Irbesartan—Vision blurred—Methotrexate—colon cancer	0.000329	0.00102	CcSEcCtD
Irbesartan—Constipation—Capecitabine—colon cancer	0.000327	0.00101	CcSEcCtD
Irbesartan—Pain—Capecitabine—colon cancer	0.000327	0.00101	CcSEcCtD
Irbesartan—Nausea—Fluorouracil—colon cancer	0.000325	0.00101	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—colon cancer	0.000324	0.001	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—colon cancer	0.000322	0.000999	CcSEcCtD
Irbesartan—Feeling abnormal—Capecitabine—colon cancer	0.000315	0.000976	CcSEcCtD
Irbesartan—Malaise—Methotrexate—colon cancer	0.000314	0.000974	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—colon cancer	0.000313	0.000971	CcSEcCtD
Irbesartan—Gastrointestinal pain—Capecitabine—colon cancer	0.000313	0.000969	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—colon cancer	0.000312	0.000967	CcSEcCtD
Irbesartan—Cough—Methotrexate—colon cancer	0.000304	0.000943	CcSEcCtD
Irbesartan—Urticaria—Capecitabine—colon cancer	0.000304	0.000941	CcSEcCtD
Irbesartan—Abdominal pain—Capecitabine—colon cancer	0.000302	0.000936	CcSEcCtD
Irbesartan—Body temperature increased—Capecitabine—colon cancer	0.000302	0.000936	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—colon cancer	0.000297	0.00092	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—colon cancer	0.000297	0.00092	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—colon cancer	0.000297	0.00092	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000295	0.000914	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—colon cancer	0.000293	0.000909	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—colon cancer	0.000285	0.000882	CcSEcCtD
Irbesartan—Infection—Methotrexate—colon cancer	0.000283	0.000876	CcSEcCtD
Irbesartan—Hypersensitivity—Capecitabine—colon cancer	0.000282	0.000873	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—colon cancer	0.000279	0.000865	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—colon cancer	0.000279	0.000863	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—colon cancer	0.000276	0.000857	CcSEcCtD
Irbesartan—Hyperhidrosis—Methotrexate—colon cancer	0.000275	0.000853	CcSEcCtD
Irbesartan—Asthenia—Capecitabine—colon cancer	0.000274	0.00085	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—colon cancer	0.000271	0.000841	CcSEcCtD
Irbesartan—Pruritus—Capecitabine—colon cancer	0.00027	0.000838	CcSEcCtD
Irbesartan—Hypotension—Methotrexate—colon cancer	0.000266	0.000824	CcSEcCtD
Irbesartan—Diarrhoea—Capecitabine—colon cancer	0.000262	0.000811	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000259	0.000803	CcSEcCtD
Irbesartan—Paraesthesia—Methotrexate—colon cancer	0.000256	0.000792	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—colon cancer	0.000254	0.000786	CcSEcCtD
Irbesartan—Somnolence—Methotrexate—colon cancer	0.000253	0.000784	CcSEcCtD
Irbesartan—Dizziness—Capecitabine—colon cancer	0.000253	0.000783	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—colon cancer	0.000251	0.000776	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—colon cancer	0.000247	0.000767	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Methotrexate—colon cancer	0.000246	0.000761	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—colon cancer	0.000245	0.00076	CcSEcCtD
Irbesartan—Pain—Methotrexate—colon cancer	0.000243	0.000754	CcSEcCtD
Irbesartan—Vomiting—Capecitabine—colon cancer	0.000243	0.000753	CcSEcCtD
Irbesartan—Rash—Capecitabine—colon cancer	0.000241	0.000747	CcSEcCtD
Irbesartan—Dermatitis—Capecitabine—colon cancer	0.000241	0.000746	CcSEcCtD
Irbesartan—Headache—Capecitabine—colon cancer	0.000239	0.000742	CcSEcCtD
Irbesartan—Feeling abnormal—Methotrexate—colon cancer	0.000235	0.000727	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—colon cancer	0.000233	0.000721	CcSEcCtD
Irbesartan—Nausea—Capecitabine—colon cancer	0.000227	0.000704	CcSEcCtD
Irbesartan—Urticaria—Methotrexate—colon cancer	0.000226	0.000701	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—colon cancer	0.000225	0.000697	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—colon cancer	0.000225	0.000697	CcSEcCtD
Irbesartan—Hypersensitivity—Methotrexate—colon cancer	0.00021	0.00065	CcSEcCtD
Irbesartan—Asthenia—Methotrexate—colon cancer	0.000204	0.000633	CcSEcCtD
Irbesartan—Pruritus—Methotrexate—colon cancer	0.000201	0.000624	CcSEcCtD
Irbesartan—Diarrhoea—Methotrexate—colon cancer	0.000195	0.000603	CcSEcCtD
Irbesartan—Dizziness—Methotrexate—colon cancer	0.000188	0.000583	CcSEcCtD
Irbesartan—Vomiting—Methotrexate—colon cancer	0.000181	0.000561	CcSEcCtD
Irbesartan—Rash—Methotrexate—colon cancer	0.000179	0.000556	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—colon cancer	0.000179	0.000556	CcSEcCtD
Irbesartan—Headache—Methotrexate—colon cancer	0.000178	0.000552	CcSEcCtD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—AKT1—colon cancer	0.000169	0.00066	CbGpPWpGaD
Irbesartan—Nausea—Methotrexate—colon cancer	0.000169	0.000524	CcSEcCtD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—NRAS—colon cancer	0.000168	0.000657	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—colon cancer	0.000166	0.000648	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	0.000166	0.000647	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—EP300—colon cancer	0.000166	0.000647	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—SRC—colon cancer	0.000165	0.000645	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—AKT1—colon cancer	0.000165	0.000644	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	0.000165	0.000643	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—EGFR—colon cancer	0.000165	0.000642	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.000165	0.000642	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—MYC—colon cancer	0.000164	0.000638	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TGFB1—colon cancer	0.000163	0.000636	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—colon cancer	0.000163	0.000635	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—HRAS—colon cancer	0.000163	0.000635	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—EP300—colon cancer	0.000163	0.000634	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—PIK3CA—colon cancer	0.000162	0.00063	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	0.000161	0.000629	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—SRC—colon cancer	0.000161	0.000629	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—VEGFA—colon cancer	0.000161	0.000628	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	0.00016	0.000626	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—AKT1—colon cancer	0.00016	0.000625	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CA7—colon cancer	0.00016	0.000624	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—EGFR—colon cancer	0.00016	0.000624	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CA7—colon cancer	0.000159	0.000619	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AXIN2—colon cancer	0.000157	0.000614	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	0.000157	0.000613	CbGpPWpGaD
Irbesartan—JUN—Immune System—BCL10—colon cancer	0.000157	0.000612	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—KRAS—colon cancer	0.000156	0.000607	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—TP53—colon cancer	0.000155	0.000606	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	0.000155	0.000605	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—EGFR—colon cancer	0.000153	0.000599	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—colon cancer	0.000153	0.000595	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—KRAS—colon cancer	0.000151	0.00059	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	0.000148	0.000576	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	0.000147	0.000574	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—colon cancer	0.000146	0.000571	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—HRAS—colon cancer	0.000145	0.000567	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—EGFR—colon cancer	0.000145	0.000566	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—KRAS—colon cancer	0.000145	0.000565	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—MYC—colon cancer	0.000145	0.000564	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—PIK3CA—colon cancer	0.000144	0.000563	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	0.000144	0.000563	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	0.000144	0.000563	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	0.000141	0.000552	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	0.000141	0.000552	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—colon cancer	0.000141	0.000551	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—AKT1—colon cancer	0.000138	0.000537	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—CDKN1A—colon cancer	0.000137	0.000536	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	0.000136	0.000532	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CA7—colon cancer	0.000136	0.000529	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—colon cancer	0.000134	0.000524	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	0.000134	0.000521	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—HRAS—colon cancer	0.000134	0.000521	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—PIK3CA—colon cancer	0.000133	0.000519	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—HRAS—colon cancer	0.000132	0.000516	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—AKT1—colon cancer	0.000132	0.000515	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—EP300—colon cancer	0.000131	0.00051	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—AKT1—colon cancer	0.000128	0.000501	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—BCL2L1—colon cancer	0.000126	0.000492	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—PIK3CA—colon cancer	0.000126	0.000491	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	0.000125	0.000489	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—VEGFA—colon cancer	0.000124	0.000483	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—colon cancer	0.000124	0.000483	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—AKT1—colon cancer	0.000124	0.000482	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—HRAS—colon cancer	0.000123	0.000481	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	0.000121	0.000473	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—FGFR3—colon cancer	0.000121	0.000471	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ODC1—colon cancer	0.000118	0.000461	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CHST5—colon cancer	0.000118	0.000461	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—AKT1—colon cancer	0.000118	0.00046	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—AKT1—colon cancer	0.000117	0.000456	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—HRAS—colon cancer	0.000116	0.000454	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—colon cancer	0.000116	0.000454	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	0.000114	0.000443	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—AKT1—colon cancer	0.000113	0.000442	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	0.000109	0.000424	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CA7—colon cancer	0.000105	0.000408	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—AKT1—colon cancer	0.000103	0.000401	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	0.000102	0.000399	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ODC1—colon cancer	9.69e-05	0.000378	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CHST5—colon cancer	9.69e-05	0.000378	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ODC1—colon cancer	9.61e-05	0.000375	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CHST5—colon cancer	9.61e-05	0.000375	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—colon cancer	9.36e-05	0.000365	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD8A—colon cancer	8.59e-05	0.000335	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ABCB1—colon cancer	8.58e-05	0.000335	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—TYMS—colon cancer	8.42e-05	0.000329	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ODC1—colon cancer	8.21e-05	0.00032	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CHST5—colon cancer	8.21e-05	0.00032	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—FGFR3—colon cancer	7.75e-05	0.000302	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	7.55e-05	0.000294	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CTNNB1—colon cancer	7.53e-05	0.000294	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CDKN1A—colon cancer	7.35e-05	0.000287	CbGpPWpGaD
Irbesartan—JUN—Immune System—BCL2L1—colon cancer	7.35e-05	0.000287	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—APC—colon cancer	7.12e-05	0.000278	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—NRAS—colon cancer	7.12e-05	0.000278	CbGpPWpGaD
Irbesartan—JUN—Immune System—FGFR3—colon cancer	7.03e-05	0.000274	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EP300—colon cancer	6.99e-05	0.000273	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—SRC—colon cancer	6.8e-05	0.000265	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—BRAF—colon cancer	6.69e-05	0.000261	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NRAS—colon cancer	6.54e-05	0.000255	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—EGFR—colon cancer	6.48e-05	0.000253	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ODC1—colon cancer	6.34e-05	0.000247	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CHST5—colon cancer	6.34e-05	0.000247	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—PIK3CA—colon cancer	6.2e-05	0.000242	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—KRAS—colon cancer	6.12e-05	0.000239	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FGFR3—colon cancer	6.08e-05	0.000237	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PPARG—colon cancer	5.97e-05	0.000233	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—colon cancer	5.96e-05	0.000233	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDH1—colon cancer	5.94e-05	0.000232	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	5.94e-05	0.000232	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KRAS—colon cancer	5.63e-05	0.00022	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—PIK3CA—colon cancer	5.63e-05	0.000219	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—APC—colon cancer	5.58e-05	0.000218	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—NRAS—colon cancer	5.58e-05	0.000218	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—BRAF—colon cancer	5.25e-05	0.000205	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—HRAS—colon cancer	5.21e-05	0.000203	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—PIK3CA—colon cancer	5.17e-05	0.000202	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—colon cancer	5.09e-05	0.000198	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AKT1—colon cancer	5.06e-05	0.000197	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CASP3—colon cancer	5.01e-05	0.000196	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—EP300—colon cancer	4.94e-05	0.000193	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CCND1—colon cancer	4.88e-05	0.00019	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.87e-05	0.00019	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—PIK3CA—colon cancer	4.86e-05	0.00019	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CTNNB1—colon cancer	4.83e-05	0.000189	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ABCB1—colon cancer	4.83e-05	0.000188	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—KRAS—colon cancer	4.81e-05	0.000187	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HRAS—colon cancer	4.79e-05	0.000187	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TYMS—colon cancer	4.74e-05	0.000185	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CDKN1A—colon cancer	4.72e-05	0.000184	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—colon cancer	4.69e-05	0.000183	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—colon cancer	4.6e-05	0.000179	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FGFR3—colon cancer	4.54e-05	0.000177	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EP300—colon cancer	4.49e-05	0.000175	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PIK3CA—colon cancer	4.41e-05	0.000172	CbGpPWpGaD
Irbesartan—JUN—Immune System—CTNNB1—colon cancer	4.38e-05	0.000171	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SRC—colon cancer	4.37e-05	0.00017	CbGpPWpGaD
Irbesartan—JUN—Immune System—CDKN1A—colon cancer	4.28e-05	0.000167	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—colon cancer	4.26e-05	0.000166	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—colon cancer	4.23e-05	0.000165	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NRAS—colon cancer	4.2e-05	0.000164	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—APC—colon cancer	4.17e-05	0.000163	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—HRAS—colon cancer	4.08e-05	0.000159	CbGpPWpGaD
Irbesartan—JUN—Immune System—EP300—colon cancer	4.07e-05	0.000159	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—colon cancer	3.97e-05	0.000155	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.97e-05	0.000155	CbGpPWpGaD
Irbesartan—JUN—Immune System—SRC—colon cancer	3.96e-05	0.000155	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CASP3—colon cancer	3.93e-05	0.000153	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—BRAF—colon cancer	3.92e-05	0.000153	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MYC—colon cancer	3.92e-05	0.000153	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TGFB1—colon cancer	3.91e-05	0.000152	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—EP300—colon cancer	3.9e-05	0.000152	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.83e-05	0.00015	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCND1—colon cancer	3.83e-05	0.000149	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—colon cancer	3.83e-05	0.000149	CbGpPWpGaD
Irbesartan—JUN—Immune System—NRAS—colon cancer	3.81e-05	0.000149	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CTNNB1—colon cancer	3.79e-05	0.000148	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CDKN1A—colon cancer	3.71e-05	0.000145	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.65e-05	0.000142	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KRAS—colon cancer	3.62e-05	0.000141	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—colon cancer	3.61e-05	0.000141	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EP300—colon cancer	3.53e-05	0.000138	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—colon cancer	3.47e-05	0.000135	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SRC—colon cancer	3.43e-05	0.000134	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.39e-05	0.000132	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARG—colon cancer	3.36e-05	0.000131	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—colon cancer	3.34e-05	0.00013	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PIK3CA—colon cancer	3.32e-05	0.00013	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NRAS—colon cancer	3.3e-05	0.000129	CbGpPWpGaD
Irbesartan—JUN—Immune System—KRAS—colon cancer	3.28e-05	0.000128	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—colon cancer	3.22e-05	0.000125	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.19e-05	0.000124	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.12e-05	0.000122	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ABCB1—colon cancer	3.12e-05	0.000122	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—HRAS—colon cancer	3.07e-05	0.00012	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MYC—colon cancer	3.07e-05	0.00012	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFB1—colon cancer	3.06e-05	0.00012	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TYMS—colon cancer	3.06e-05	0.00012	CbGpPWpGaD
Irbesartan—JUN—Immune System—PIK3CA—colon cancer	3.01e-05	0.000118	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—colon cancer	3e-05	0.000117	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CASP3—colon cancer	2.94e-05	0.000115	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3CA—colon cancer	2.89e-05	0.000113	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCND1—colon cancer	2.86e-05	0.000112	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KRAS—colon cancer	2.84e-05	0.000111	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CTNNB1—colon cancer	2.83e-05	0.000111	CbGpPWpGaD
Irbesartan—JUN—Immune System—HRAS—colon cancer	2.79e-05	0.000109	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CDKN1A—colon cancer	2.77e-05	0.000108	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—colon cancer	2.72e-05	0.000106	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.67e-05	0.000104	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—colon cancer	2.64e-05	0.000103	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EP300—colon cancer	2.63e-05	0.000103	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PIK3CA—colon cancer	2.61e-05	0.000102	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.6e-05	0.000101	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ABCB1—colon cancer	2.56e-05	9.99e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SRC—colon cancer	2.56e-05	9.99e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ABCB1—colon cancer	2.54e-05	9.91e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—colon cancer	2.52e-05	9.84e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TYMS—colon cancer	2.52e-05	9.81e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—colon cancer	2.49e-05	9.73e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TYMS—colon cancer	2.49e-05	9.73e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NRAS—colon cancer	2.46e-05	9.61e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—colon cancer	2.46e-05	9.6e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HRAS—colon cancer	2.41e-05	9.41e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.36e-05	9.2e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—colon cancer	2.36e-05	9.2e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MYC—colon cancer	2.3e-05	8.95e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFB1—colon cancer	2.29e-05	8.93e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—colon cancer	2.24e-05	8.76e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.22e-05	8.65e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—EP300—colon cancer	2.2e-05	8.58e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARG—colon cancer	2.17e-05	8.47e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCB1—colon cancer	2.17e-05	8.47e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TYMS—colon cancer	2.13e-05	8.31e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—colon cancer	2.13e-05	8.31e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KRAS—colon cancer	2.12e-05	8.27e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CA—colon cancer	1.95e-05	7.6e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.92e-05	7.49e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—colon cancer	1.88e-05	7.35e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HRAS—colon cancer	1.8e-05	7.03e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARG—colon cancer	1.78e-05	6.95e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARG—colon cancer	1.77e-05	6.89e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—colon cancer	1.71e-05	6.66e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCB1—colon cancer	1.67e-05	6.53e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TYMS—colon cancer	1.64e-05	6.42e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.64e-05	6.4e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CA—colon cancer	1.63e-05	6.35e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—colon cancer	1.59e-05	6.21e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARG—colon cancer	1.51e-05	5.89e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—EP300—colon cancer	1.42e-05	5.54e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—colon cancer	1.4e-05	5.47e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—colon cancer	1.39e-05	5.42e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—colon cancer	1.33e-05	5.18e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—colon cancer	1.19e-05	4.63e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—EP300—colon cancer	1.17e-05	4.55e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARG—colon cancer	1.17e-05	4.55e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—EP300—colon cancer	1.16e-05	4.51e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CA—colon cancer	1.05e-05	4.1e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—EP300—colon cancer	9.88e-06	3.85e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—colon cancer	9.17e-06	3.58e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CA—colon cancer	8.63e-06	3.36e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—colon cancer	8.58e-06	3.35e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CA—colon cancer	8.55e-06	3.34e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—EP300—colon cancer	7.62e-06	2.97e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CA—colon cancer	7.31e-06	2.85e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—colon cancer	7.05e-06	2.75e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—colon cancer	6.99e-06	2.72e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—colon cancer	5.97e-06	2.33e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CA—colon cancer	5.64e-06	2.2e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—colon cancer	4.61e-06	1.8e-05	CbGpPWpGaD
